Avutometinib Plus Defactinib Demonstrates Promising Activity in Recurrent LGSOC
June 6, 2023 7:03 amTreatment with avutometinib plus defactinib elicited high responses among patients with recurrent low grade serous ovarian cancer compared with avutometinib monotherapy, supporting the use of the combination in this patient population regardless of KRAS status, according to data from the … Read more